

# Jeffrey A Jones

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2182566/publications.pdf>

Version: 2024-02-01

104  
papers

7,246  
citations

182225

30  
h-index

62345

84  
g-index

104  
all docs

104  
docs citations

104  
times ranked

7749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Repair-Assisted Damage Detection Reveals Biological Disparities in Prostate Cancer between African Americans and European Americans. <i>Cancers</i> , 2022, 14, 1012.	1.7	4
2	Lipid Alterations in African American Men with Prostate Cancer. <i>Metabolites</i> , 2022, 12, 8.	1.3	4
3	Space Radiation Protection Countermeasures in Microgravity and Planetary Exploration. <i>Life</i> , 2021, 11, 829.	1.1	13
4	Biologically-Based and Physiochemical Life Support and In Situ Resource Utilization for Exploration of the Solar System—Reviewing the Current State and Defining Future Development Needs. <i>Life</i> , 2021, 11, 844.	1.1	10
5	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	0.8	71
6	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	3.2	3
7	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. <i>Lancet Haematology</i> , 2019, 6, e366-e374.	2.2	49
8	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA—update 2018. <i>Nature Reviews Urology</i> , 2019, 16, 377-386.	1.9	51
9	Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib. <i>Blood Advances</i> , 2019, 3, 116-118.	2.5	28
10	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019, 60, 1438-1446.	0.6	12
11	ERR1- and PGC1 $\beta$ -associated mitochondrial alterations correlate with pan-cancer disparity in African Americans. <i>Journal of Clinical Investigation</i> , 2019, 129, 2351-2356.	3.9	24
12	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	0.6	122
13	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1008-1011.	0.6	29
14	A single-center retrospective cohort study of first-line R <sup>2</sup> EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	1.2	53
15	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	1.2	37
16	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017, 129, 2581-2584.	0.6	161
17	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e114-e126.	2.2	181
18	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. <i>British Journal of Haematology</i> , 2017, 178, 286-291.	1.2	55

#	ARTICLE	IF	CITATIONS
19	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. <i>Cancer Medicine</i> , 2017, 6, 778-787.	1.3	15
20	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017, 129, 553-560.	0.6	193
21	BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 92.	0.4	8
22	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	2.5	123
23	Ibrutinib treatment improves T cell number and function in CLL patients. <i>Journal of Clinical Investigation</i> , 2017, 127, 3052-3064.	3.9	280
24	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. <i>Blood</i> , 2017, 130, 830-830.	0.6	27
25	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	0.6	102
26	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2212-2215.	0.6	13
27	Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1989-1997.	0.8	19
28	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	5.1	290
29	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1137-1143.	0.8	31
30	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. <i>Cancer Immunology Research</i> , 2016, 4, 698-707.	1.6	15
31	Sixty-minute infusion rituximab protocol allows for safe and efficient workflow. <i>Supportive Care in Cancer</i> , 2016, 24, 1125-1129.	1.0	9
32	Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215.	0.6	25
33	a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2016, 128, 1776-1776.	0.6	3
34	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. <i>Blood</i> , 2016, 128, 2040-2040.	0.6	2
35	Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis. <i>Blood</i> , 2016, 128, 3221-3221.	0.6	3
36	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. <i>Blood</i> , 2016, 128, 3238-3238.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. <i>Blood</i> , 2016, 128, 4385-4385.	0.6	2
38	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. <i>Blood</i> , 2016, 128, 4386-4386.	0.6	2
39	Major Bleeding Complications Among Patients Treated with Ibrutinib and Concomitant Antiplatelet, Anticoagulant, or Supplemental Therapy. <i>Blood</i> , 2016, 128, 4387-4387.	0.6	8
40	A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , 2016, 128, 4388-4388.	0.6	2
41	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	0.6	8
42	Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients. <i>Blood</i> , 2016, 128, 5583-5583.	0.6	3
43	Trametinib for the Treatment of IGHV4-34, MAP2K1 Mutant Variant Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5598-5598.	0.6	3
44	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	0.6	48
45	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	0.6	22
46	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	0.6	0
47	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016, 128, 5986-5986.	0.6	0
48	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. <i>Blood</i> , 2016, 128, 2767-2767.	0.6	0
49	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	0.6	19
50	Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. <i>Haematologica</i> , 2015, 100, e18-e20.	1.7	7
51	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	1.2	8
52	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	3.4	498
53	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
54	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4322-4327.	3.3	38

#	ARTICLE	IF	CITATIONS
55	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	0.6	618
56	Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. <i>JAMA Oncology</i> , 2015, 1, 684.	3.4	35
57	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	0.6	10
58	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953.	0.6	2
59	Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib Therapy. <i>Blood</i> , 2015, 126, 715-715.	0.6	26
60	Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. <i>Blood</i> , 2015, 126, 833-833.	0.6	15
61	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. <i>Blood</i> , 2015, 126, 318-318.	0.6	0
62	Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. <i>MAbs</i> , 2014, 6, 748-754.	2.6	37
63	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 19-24.	2.0	26
64	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	5.1	438
65	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1025-1029.	0.4	11
66	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. <i>Blood</i> , 2014, 124, 1990-1990.	0.6	10
67	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-17 Trial. <i>Blood</i> , 2014, 124, 327-327.	0.6	33
68	Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 4696-4696.	0.6	12
69	Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 568-574.	0.2	72
70	Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101. <i>Leukemia and Lymphoma</i> , 2013, 54, 2654-2659.	0.6	9
71	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 32-42.	13.9	2,019
72	B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell-Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In-Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo. <i>Blood</i> , 2013, 122, 4185-4185.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 871-871.	0.6	11
74	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. <i>Blood</i> , 2013, 122, 2872-2872.	0.6	0
75	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. <i>Haematologica</i> , 2012, 97, 423-427.	1.7	17
76	Weight gain after lymphoma treatment: fat or fiction?. <i>Leukemia and Lymphoma</i> , 2012, 53, 517-518.	0.6	0
77	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. <i>Blood</i> , 2012, 120, 1262-1273.	0.6	91
78	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. <i>Cancer Cell</i> , 2012, 21, 694-708.	7.7	122
79	Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells. <i>Blood</i> , 2012, 120, 775-775.	0.6	2
80	Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling. <i>Blood</i> , 2012, 120, 3866-3866.	0.6	0
81	Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.. <i>Blood</i> , 2012, 120, 2473-2473.	0.6	0
82	Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 2075-2075.	0.6	0
83	A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2012, 120, 1800-1800.	0.6	0
84	The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1362-1362.	0.6	0
85	Choosing first-line therapy for chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1379-1390.	1.1	14
86	The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 3113-3113.	0.6	0
87	A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,. <i>Blood</i> , 2011, 118, 3912-3912.	0.6	2
88	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. <i>Blood</i> , 2011, 118, 1791-1791.	0.6	0
89	Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial,. <i>Blood</i> , 2011, 118, 3910-3910.	0.6	0
90	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. <i>Blood</i> , 2011, 118, 622-622.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.. Blood, 2011, 118, 3707-3707.	0.6	0
92	Phosphatidylinositol 3-kinase-Î inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, 2010, 116, 2078-2088.	0.6	523
93	Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 1649-1657.	0.6	42
94	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. Blood, 2010, 116, 1378-1378.	0.6	0
95	Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease. Journal of Clinical Oncology, 2009, 27, 6012-6018.	0.8	212
96	In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP).. Blood, 2009, 114, 1398-1398.	0.6	1
97	In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies. Cancer, 2008, 112, 1096-1105.	2.0	63
98	A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma. Blood, 2008, 112, 3053-3053.	0.6	1
99	CAL-101, a Selective Inhibitor of the p110Î Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease. Blood, 2008, 112, 3165-3165.	0.6	4
100	Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 3300-3300.	0.6	0
101	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. Blood, 2008, 112, 3169-3169.	0.6	0
102	del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.. Blood, 2007, 110, 2073-2073.	0.6	1
103	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. Blood, 2007, 110, 3104-3104.	0.6	3
104	Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.. Blood, 2007, 110, 3128-3128.	0.6	5